UCB9608 is a Potent, Orally Bioavailable PI4KIIIβ Inhibitor. UCB9608 showed the improved metabolic stability and excellent pharmacokinetic profile. UCB9608 is an 11 nM PI4KIIIβ inhibitor that inhibits the HuMLR response with IC50 = 37 nM. Its potency and excellent ADME properties make it an ideal compound for future use as an in vitro and in vivo probe to elucidate the emerging role of PI4KIIIβ inhibition in immune processes.
For research use only. We do not sell to patients.
Name | UCB9608 |
---|---|
Iupac Chemical Name | (3S)-4-(6-amino-1-methyl-pyrazolo[3,4-d]pyrimidin-4-yl)-N-(4-methoxy-2-methyl-phenyl)-3-methyl-piperazine-1-carboxamide |
Synonyms | UCB9608; UCB-9608; UCB 9608. |
Molecular Formula | C20H26N8O2 |
Molecular Weight | 410.482 |
Smile | O=C(N1C[C@H](C)N(C2=C3C(N(C)N=C3)=NC(N)=N2)CC1)NC4=CC=C(OC)C=C4 |
InChiKey | WRONAJQPZWDYAR-ZDUSSCGKSA-N |
InChi | InChI=1S/C20H26N8O2/c1-12-9-14(30-4)5-6-16(12)23-20(29)27-7-8-28(13(2)11-27)18-15-10-22-26(3)17(15)24-19(21)25-18/h5-6,9-10,13H,7-8,11H2,1-4H3,(H,23,29)(H2,21,24,25)/t13-/m0/s1 |
CAS Number | 2244989-34-0 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | Solid powder |
---|---|
Purity | 98% Min. |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Solubility | Soluble in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |
1: Reuberson J, Horsley H, Franklin RJ, Ford D, Neuss J, Brookings D, Huang Q,
Vanderhoydonck B, Gao LJ, Jang M, Herdewijn P, Ghawalkar A, Fallah-Arani F, Khan
A, Henshall J, Jairaj M, Malcolm S, Ward E, Shuttleworth L, Lin Y, Li S, Louat T,
Waer M, Herman J, Payne A, Ceska T, Doyle C, Pitt WR, Calmiano M, Augustin M,
Steinbacher S, Lammens A, Allen R. Discovery of a potent, orally bioavailable
PI4KIIIβ inhibitor (UCB9608) able to significantly prolong allogeneic organ
engraftment in vivo. J Med Chem. 2018 Jun 28. doi: 10.1021/acs.jmedchem.8b00521.
[Epub ahead of print] PubMed PMID: 29952567.